Safety and immunogenicity of a primary series and booster dose of the meningococcal serogroup B-factor H binding protein vaccine (MenB-FHbp) in healthy children aged 1-9 years: two phase 2 randomised, controlled, observer-blinded studies.

Marshall, Helen S; Vesikari, Timo; Richmond, Peter C; Wysocki, Jacek; Szenborn, Leszek; Beeslaar, Johannes; Maguire, Jason D; Balmer, Paul; O'Neill, Robert; Anderson, Annaliesa S; Prégaldien, Jean-Louis; Maansson, Roger; Jiang, Han-Qing; Perez, John L

Marshall, Helen S; Vesikari, Timo; Richmond, Peter C; Wysocki, Jacek; Szenborn, Leszek; Beeslaar, Johannes; Maguire, Jason D; Balmer, Paul; O'Neill, Robert; Anderson, Annaliesa S; Prégaldien, Jean-Louis; Maansson, Roger; Jiang, Han-Qing; Perez, John L.

Affiliation

Marshall HS; Vaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, North Adelaide, SA, Australia; Robinson Research Institute and Adelaide Medical School, The University of Adelaide, Adelaide, SA, Australia. Electronic address: helen.marshall@adelaide.edu.au.
Vesikari T; Nordic Research Network, Tampere, Finland.
Richmond PC; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, WA, Australia; Perth Children's Hospital, Nedlands, WA, Australia.
Wysocki J; Poznan University of Medical Sciences, Poznan, Poland.
Szenborn L; Clinical Department of Pediatric Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland.
Beeslaar J; Pfizer Vaccine Clinical Research and Development, Hurley, UK.
Maguire JD; Pfizer Vaccine Clinical Research and Development, Pearl River, NY, USA.
Balmer P; Pfizer Vaccine Medical Development and Scientific/Clinical Affairs, Collegeville, PA, USA.
O'Neill R; Pfizer Vaccine Research and Development, Pearl River, NY, USA.
Anderson AS; Pfizer Vaccine Research and Development, Pearl River, NY, USA.
Prégaldien JL; Pfizer Vaccine Clinical Research and Development, Brussels, Belgium.
Maansson R; Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA.
Jiang HQ; Pfizer Vaccine Clinical Research and Development, Pearl River, NY, USA.
Perez JL; Pfizer Vaccine Clinical Research and Development, Collegeville, PA, USA.

Lancet Infect Dis ; 23(1): 103-116, 2023 01.

Article de En | MEDLINE | ID: mdl-36087588

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Vaccins antiméningococciques / Neisseria meningitidis sérogroupe B / Infections à méningocoques Type d'étude: Clinical_trials / Guideline Limites: Adolescent / Child / Child, preschool / Humans Pays/Région comme sujet: Oceania Langue: En Journal: Lancet Infect Dis Sujet du journal: DOENCAS TRANSMISSIVEIS Année: 2023 Type de document: Article Pays de publication: États-Unis d'Amérique

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google